Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.

Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sánchez C, Haddjeri N.

Int J Neuropsychopharmacol. 2007 Feb;10(1):31-40. Epub 2006 Feb 1.

PMID:
16448580
2.

[Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].

Mnie-Filali O, El Mansari M, Scarna H, Zimmer L, Sánchez C, Haddjeri N.

Encephale. 2007 Dec;33(6):965-72. doi: 10.1016/j.encep.2007.11.001. Epub 2007 Dec 11. Review. French.

PMID:
18789789
3.

Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.

Zhong H, Haddjeri N, Sánchez C.

Psychopharmacology (Berl). 2012 Jan;219(1):1-13. doi: 10.1007/s00213-011-2463-5. Epub 2011 Sep 8. Review.

PMID:
21901317
4.

A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?

Sanchez C, Reines EH, Montgomery SA.

Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. doi: 10.1097/YIC.0000000000000023. Review.

5.
6.
8.

Clinical pharmacokinetics of selective serotonin reuptake inhibitors.

van Harten J.

Clin Pharmacokinet. 1993 Mar;24(3):203-20. Review.

PMID:
8384945
9.

Escitalopram versus citalopram: the surprising role of the R-enantiomer.

Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C.

Psychopharmacology (Berl). 2004 Jul;174(2):163-76. Review.

PMID:
15160261
10.

The pharmacogenetics of the selective serotonin reuptake inhibitors.

Brøsen K.

Clin Investig. 1993 Dec;71(12):1002-9. Review.

PMID:
8124052
11.

Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake.

Pinna G, Costa E, Guidotti A.

Psychopharmacology (Berl). 2006 Jun;186(3):362-72. Epub 2006 Jan 24. Review.

PMID:
16432684
12.

Escitalopram.

Aronson S, Delgado P.

Drugs Today (Barc). 2004 Feb;40(2):121-31. Review.

PMID:
15045034
13.

Effects of citalopram on serotonin and CRF systems in the midbrain of primates with differences in stress sensitivity.

Bethea CL, Lima FB, Centeno ML, Weissheimer KV, Senashova O, Reddy AP, Cameron JL.

J Chem Neuroanat. 2011 Jul;41(4):200-18. doi: 10.1016/j.jchemneu.2011.05.010. Epub 2011 Jun 6. Review.

14.

Development of PET/SPECT ligands for the serotonin transporter.

Scheffel U, Dannals RF, Suehiro M, Ricaurte GA, Carroll FI, Kuhar MJ, Wagner HN Jr.

NIDA Res Monogr. 1994;138:111-30. Review.

PMID:
7603538
15.

Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.

Leonard B, Taylor D.

J Psychopharmacol. 2010 Aug;24(8):1143-52. doi: 10.1177/0269881109349835. Epub 2010 Feb 10. Review.

16.

Antidepressant medication use during breastfeeding.

Lanza di Scalea T, Wisner KL.

Clin Obstet Gynecol. 2009 Sep;52(3):483-97. doi: 10.1097/GRF.0b013e3181b52bd6. Review.

17.

Escitalopram: a review of its use in the management of anxiety disorders.

Dhillon S, Scott LJ, Plosker GL.

CNS Drugs. 2006;20(9):763-90. Review.

PMID:
16953656
18.

Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

DeVane CL.

Cell Mol Neurobiol. 1999 Aug;19(4):443-66. Review.

PMID:
10379420
19.

The effect of increased serotonergic neurotransmission on aggression: a critical meta-analytical review of preclinical studies.

Carrillo M, Ricci LA, Coppersmith GA, Melloni RH Jr.

Psychopharmacology (Berl). 2009 Aug;205(3):349-68. doi: 10.1007/s00213-009-1543-2. Epub 2009 Apr 30. Review.

PMID:
19404614
20.

Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders.

Albayrak Y, Hashimoto K.

Adv Exp Med Biol. 2017;964:153-161. doi: 10.1007/978-3-319-50174-1_11. Review.

PMID:
28315270

Supplemental Content

Support Center